DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children

MT Newswires Live

Mar 24

DBV Technologies (DBVT) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.

The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.

DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's "substantial doubt" about its ability to continue as a going concern.

The company said it is actively reviewing potential financing and strategic options with its financial advisers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2521795133"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521795133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2521795133?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 16:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521795133","market":"hk","top_or_hot":-1,"title":"DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children","media":"MT Newswires Live","content":"<html><body><p> DBV Technologies (DBVT) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.</p><p>The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.</p><p>DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's \"substantial doubt\" about its ability to continue as a going concern.</p><p>The company said it is actively reviewing potential financing and strategic options with its financial advisers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-24 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> DBV Technologies (DBVT) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.</p><p>The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.</p><p>DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's \"substantial doubt\" about its ability to continue as a going concern.</p><p>The company said it is actively reviewing potential financing and strategic options with its financial advisers.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521795133","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521795133","pubTimestamp":1742804425,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"DBV Technologies  said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's \"substantial doubt\" about its ability to continue as a going concern.The company said it is actively reviewing potential financing and strategic options with its financial advisers.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DBV":"Invesco DB G10 Currency Harvest Fund","DBVT":"DBV Technologies S.A."},"translate_title":"DBV Technologies的花生过敏贴片清除了FDA对儿童的安全障碍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBVT":0.9,"DBV":1},"content_text":"DBV Technologies (DBVT) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's \"substantial doubt\" about its ability to continue as a going concern.The company said it is actively reviewing potential financing and strategic options with its financial advisers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}